KMAP BULLETIN: Preferred Drug List Update March 2025

Date: 03/18/25

Effective with dates of service on or after March 1, 2025, the following medications will become non-preferred and require a Preferred Drug List (PDL) Prior Authorization (PA):

Zoryve® (roflumilast)
Vtama® (tapinarof)
Ebglyss™ (lebrikizumab-lbkz)
Nemluvio® (nemolizumab-ilto)
Bimzelx® (bimekizumab-bkzx)
Cimzia® (certolizumab pegol)
Tremfya® (guselkumab)
Voquezna® (vonoprazan)
Opsynvi® (macitentan/Tadalafil)
Nexiclon™ XR (clonidine ER)

Effective with dates of service on or after March 1, 2025, the following medications are considered preferred:

Catapres-TTS (clonidine, transdermal)
Catapres (clonidine)
Tenex (guanfacine)
Aldomet (methyldopa)
Paxlovid (nirmatrelvir/ritonavir)

Note: The effective date of the policy is March 1, 2025. The implementation of State policy by the KanCare Managed Care Organizations (MCOs) may vary from the date noted in the Kansas Medical Assistance Program (KMAP) bulletins. The KanCare Open Claims Resolution Log on the KMAP Bulletins page documents the MCO system status for policy implementation and any associated reprocessing completion dates once the policy is implemented.